View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
December 30, 2021updated 07 Jan 2022 6:15am

Coronavirus company news summary – Oravax signs Covid-19 vaccines pre-purchase agreement – USPTO grants patent of Tevogen Bio’s T cell therapy compositions

By Srivani Venna

MyMD Pharmaceuticals’ investment company Oravax Medical has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax’s oral Covid-19 vaccine. The cooperation and purchase agreement has been signed for an initial pre-order of ten million oral vaccine doses from Oravax and consists of milestone payments. Under the agreement, Tan Thanh Holdings will sell the vaccine in development throughout the Association of Southeast Asian Nations (ASEAN).

The US Patent and Trademark Office (USPTO) has granted patent of the pharmaceutical compositions of Tevogen Bio’s experimental SARS-CoV-2 Specific Allogeneic T cell therapy to treat Covid-19. The therapy is being evaluated in a clinical trial for high-risk patients at Thomas Jefferson University in Philadelphia. The USPTO patent supports the company’s growing IP portfolio which already includes a patent that covers method of Covid-19 treatment with the help of SARS-COV-2 Specific Allogeneic Cytotoxic T Lymphocytes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology